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In the United States, 12% of women are typically diagnosed with breast cancer, 
where 20-30% of these cases are identified as Triple Negative Breast Cancer (TNBC). In 
the state of Arizona, 810 deaths occur due to breast cancer and more than 4,600 cases are 
diagnosed every year (American Cancer Society). The lack of estrogen, progesterone, and 
HER2 receptors in TNBC makes discovery of targeted therapies further challenging. To 
tackle this issue, a novel multi-component drug vehicle is presented. Previously, we have 
shown that mitoxantrone, a DNA damaging drug, can sensitize TNBC cells to TRAIL, 
which is a protein that can selectively kill cancer cells. In this current study, we have 
formulated aminoglycoside-derived nanoparticles (liposomes) loaded with mitoxantrone, 
PARP inhibitors, for delivery to cancer cells. PARP inhibitors are helpful in preventing 
cancer cells from repairing their DNA following damage with other drugs 
(e.g. mitoxantrone). Various treatment liposome groups, consisting of lipid-containing 
polymers (lipopolymers) synthesized in our laboratory, were formulated and characterized 
for their size, surface charge, and stability. PARP inhibitors and treatment of cells for in-
vitro and in-vivo experiments with these liposomes resulted in synergistic death of cancer 
cells. Finally, studies to evaluate the pre-clinical efficacy of these approaches 
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 Cancer continues to be a deadly disease affecting men and women of various ages 
in the United States and all over the world. Approximately 40% of the population will face 
this deadly disease at some stage of their life.1 Specifically, 12% of women in the United 
States are typically diagnosed with breast cancer, where 20-30% of these cases are 
identified as Triple Negative Breast Cancer (TNBC). Women diagnosed with TNBC have 
lower five-year survival rates (77%) than other types of breast cancers (93%).2 Triple 
Negative Breast Cancer is known to be more aggressive as it can more easily spread tumors 
to other organs and also recur even after rigorous treatments. TNBC tumors are called 
“triple-negative” due to the lack of three hormone growth receptors: HER-2, Estrogen, and 
Progesterone (Figure 1.1.1) Receptor positive cells allow chemotherapeutic drugs to arrive 
at receptor site and block hormone attachment to kill tumor cells. However, for TNBC 
cells, lack of receptors makes this strategy complicated and ineffective. Therefore, 
conventional methods of chemotherapy, and drugs targeted to those common breast growth 
receptors are ineffective.2,3 Other treatments such as local breast surgeries and mastectomy 
also have challenges with difficult strategies and high chances of tumor and local regional 
recurrence (LRR).2, 4 As stated earlier, the lack of estrogen, progesterone, and HER2 
receptors in TNBC makes discovery of targeted therapies further challenging. TNBC 
tumors are also closely associated with BRCA-1 and BRCA-2 mutations which are tumor 
suppressor genes that aid in DNA repair in cells.5 Taking advantage of this association 






Figure 1.1.1 Triple Negative Breast Cancer Cell with three negative receptors. 
 
Various chemotherapy agents are known widely in oncology research fields. One 
such agent is antineoplastic, a synthetic anthracycline derivative used in different cancer 
treatments, both in research and clinical settings. An anthracycline agent is a red aromatic 
polyketide occurring in various forms that has high anti-tumor activity. A few examples of 
these agents include doxorubicin, Adriamycin, and mitoxantrone. An added benefit is the 
potential to generate free oxygen radicals which is a strategy in damaging cell DNA via 
strand breaks. Anthracyclines easily diffuse through cellular membranes with its high 
affinity to various proteasomes in the cytoplasm which forms a complex and sent to the 
nucleus for binding of the anthracycline drug to DNA backbones. To tackle challenges of 
high toxicity, using an anthracycline derivative form is helpful to decrease tumor resistance 
and other potential side effects to dosage related factors. Additionally, a few other methods 
to avoid cardiotoxicity risks lies in delivery methods of drugs and the types of 
modifications associated with them(11,20).6, 7 It is known as a common chemotherapeutic 
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agent in acute leukemia, and non-Hodgkin’s lymphoma.8,9,10 Being an FDA approved drug 
from late 80’s, it became instrumental for leukemia, prostate, and breast cancer treatments. 
It was also FDA approved for multiple sclerosis (MS) with its rapid uptake in tissues and 
a longer half life of nine days. Doxorubucin, Mitoxantrone, Epirubicin, and few others are 
known for their mechanistic action of intercalation of DNA molecule via double strand 
breaks. They are called Topoisomerase II inhibitors and induce apoptosis (cell suicide) 
through DNA damage in human myeloid leukemia cells and observed to have potent cell 
death effects in other types of cancer cells as well. Topoisomerase II is an essential enzyme 
that aids in DNA topology modification to provide transitory double strand breaks. It 
utilizes ATP to pass a helix through the transitory breaks to aid in DNA topology repair 
and ultimate restoration of its original structure. It also is key in chromosome segregation. 
Using an inhibitor of this particular enzyme is influential in cycle disruption to promote 
apoptosis through forceful double stand breaks.  
 
Poly (ADP-ribose) polymerase (PARP) inhibitors are also an attractive molecule in 
cancer therapies targeting inhibition DNA repair pathways. PARP enzymes are a group of 
enzymes controlled by a wide variety of genes that help in catalysis to ultimately target 
various proteins in the human body. They are crucial to chromatin structure modifications, 
as well as transcription, replication, and most importantly, DNA repair. Many cells that are 
deficient in homologous recombination rely on PARP enzymes mediated DNA repair for 
survival. When DNA undergoes any single or double strand breaks, PARP is involved in 
base excision repair (BER) as a part of the complex containing DNA polymerase beta, 
DNA ligase III, XRCC1 protein. In the PARP family, each type of enzyme is a part of 
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different repair pathways with NER and BER to be the instrumental ones in DNA repair 
with chemotherapeutic agents. The versatile properties of PARP enzymes come in to play 
with its involvement in the cell cycle phases (cytokensis, G0, G1, S, G2, mitosis). Various 
studies have shown its role in G2 cell checkpoint phase as it aids in preventing damaged 
DNA strands to enter in further cell phases. PARP-1 arrives at the DNA site and releases 
nicotinamides as a result of NAD+ cleavage. After this cleavage, the chromatin structure is 
liberated to recruit proteins for scaffold modeling, allowing DNA polymerase β to attach 
any breaks and gaps.11,12   
 
When DNA damage occurs, histones near the site are phosphorylated by ATM and 
ATR molecules which aids in recruitment of binding mediators, which leads to an 
important mediator RAP80 that can identify histones near DNA damage sites through the 
ubiquitin-interacting motif (UIM). RAP80 is the recruiter of BRCA1 gene complex to the 
specific damage site. Another key characteristic of BRCA1 is its dominance in all 
checkpoints of the cell cycle to assure no damaged DNA proceeds to mitosis. Especially in 
the G1/S checkpoint phase, when DNA damage occurs, it “arrests” cells before proceeding 
to replication and division.13 The tumor suppressor gene p53 plays a large role in this phase, 
and as discussed earlier, p53 is an important biomarker for DNA damage and repair 
pathways. It prevents cyclin B and Cdc2 transcription proteins from activating to assure 
that these markers do not promote cell to progress towards mitosis.14,18 This shows that 
interference with this cell cycle is crucial and advantageous for inhibiting certain mediators 
to promote cancer cell death. As mentioned earlier when SSBs occur, the PARP inhibitor 
blocks any activity from repair protein which promotes cell degradation and leads to DSBs. 
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Both cell and pre-clinical studies have gone to prove the sensitivity of PARP deficient cells 
(PARP -/-) to DNA damaging and chemotherapeutic agents.13,14,15 This case makes the use 
of PARP inhibitors with antineoplastic or chemotherapeutic agents a useful mechanistic 
tool to target multiple apoptosis pathways.  
 
1.2. Literature Review  
In literature, various drug and gene delivery were found to be common approaches 
to treating TNBC tumors. In one study of anti-cancer effects of a novel system against 
triple negative breast cancer, the agent Aminoflavone (AF) was found effective in 
preventing TNBC tumor growth at low doses. In addition, AF was helpful in cell cycle 
arrest, apoptosis, and identified as a DNA damaging agent. AF is known to have high 
toxicity levels in clinical and in-vivo models, therefore, this study wanted to improve drug 
effects to TNBC tumor sites with low toxicity levels. A multifunctional micelle was 
formulated and conjugated with a peptide, GE11, for safe delivery of AF agents to the 
tumor site. These star-polymer micelles were prepared by various dialysis and freeze-dried 
methods to yield studies both in-vitro and in-vivo. Results revealed that AF-T (AF loaded 
GE11-conjugated targeted) micelles had significant cell death when compared to the AF-
NT (non-treated) micelles, showing cell death up to 85%. In-vivo results also were in 
accordance, with strong statistical significance (p<.001) for AF-T treated mice versus AF-
NT mice. The results overall confirmed that GE-11 binding to micelles allowed for better 
targeting to tumor cells, where AF agents were unloaded, showing smaller tumor sizes in-
vivo and higher cell death in in-vitro studies.15  
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In another study, researchers went to prove that sigma-2 was a significant receptor 
through progesterone receptor membrane component 1(PGRMC1) for TNBC tumors, to 
help further studies find a system to target this for aggressive treatments. Using different 
SMC (small mimetic compound) agents to bind to sigma-2-targeted drugs showed higher 
cytotoxicity than commonly used therapies for breast cancers (taxol). MDA-MB-231, had 
the highest sigma-2 expression of the three TNBC cell lines tested. Additionally, MDA-
MB-231 also was taxol resistant along with its high sensitivity to sigma-2 receptor SMC 
delivery methods. Specific mechanistic studies still need to explored to understand the 
apoptosis pathways in relation to sigma-2 receptor targeted therapies.  
Using receptor based targeted therapies, many studies have shown minimal cell 
survival with tailored surface properties of nanoparticles in TNBC studies. Particularly, 
Johnson. Et al synthesized reconstituted high density lipoproteins (rHDLs) with 
anthracycline anti-cancer drugs for targeting towards overexpressed scavenger receptor 
class B type 1 (SR-B1) receptors to perform characterization and cytotoxicity testing. 
These particles at 50 nm and approximately -6 to -9mV were efficient at higher half life 
circulation in blood systems. Testing the efficacy of these NPs (4 – 8 uM) and in 
comparison to free drug treatments in MDA-MB-231 (TNBC cell line), the study showed 
a significant (60-70%) decrease in cancer cell survival. Synthesized NPs were also tested 
in the H9C2 (cardiomyocyte) cell line which revealed NPs acting as a shield, increasing 
cell survival fourfold – which confirms minimal effect to cardiac tissues with 
chemotherapeutic drugs. In addition, northern blot analyses revealed a significant 
fluorescence shift of SR-B1 protein expression in MDA-MB-231 showing that mechanistic 
pathway of targeted drug delivery was instrumental. Confocal microscopy also confirmed 
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the higher uptake and efficacy (> 50% FU units) of encapsulated drugs in NPs versus 
control (free drug) treatments.26 The targeting mechanism in this paper with the supporting 
results suggest the ease of transport of rHDL NPs to the cytoplasm, avoiding major 
challenges through extracellular membrane transport.  
A recent study evaluated alternate forms of nanoparticle delivery for enhanced 
therapeutic effects in TNBC. Anti-Trop2 (an overexpressed glycoprotein in TNBC tumors) 
conjugated nanoparticles loaded with various dextran derivatives composed of 
bioreducible disulfide bonds. Doxorubicin, a commonly known anthracycline in 
chemotherapeutic studies, was also loaded and tailored to be released at tumor sites in the 
presence of glutathione (GSH). Average diameters of nanoparticles were between ranges 
of 160-190 nm, which is the appropriate size for nanocarrier methods. With various release 
and cytotoxicity studies, the GSH environment versus controls reduced the disulfide bonds 
in nanoparticles which allowed for rapid drug release (low cancer cell survival of 70-
80%).26  
1.3.Motivation 
Chemotherapy and radiation are generic treatments employed for patients with cancer 
diseases but are not tailored specifically for cancer types. Various drug delivery methods 
are used in both pre-clinical and clinical settings in the healthcare field to aim for targeted 
and controlled release of chemotherapeutic agents. Microneedles, gene and protein 
delivery, cargo as nanovaccines, and nanoparticle systems such as micelles and liposomes 
are few of the methods known and currently being developed.16,17,15,18 Particularly when 
using nanoparticles as used in this current study, various modifications to the surface 
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chemistry can aid in enhanced biological function and tumor activity at the molecular level. 
As mentioned earlier, liposomes are an efficient way to reduce the toxicity levels associated 
with drugs which is a real challenge in the field. Liposomes are spherical shaped 
amphipathic vesicles or molecules composed of a bi-layer non-toxic phospholipids.19 They 
also mimic the cell membrane structure which is instrumental when these NPs come in 
contact with cells and release any loaded molecules with responses to pH, temperature, 
radiation, etc. Using these nanometer sized vesicles is advantageous to improved stability, 
higher compatibility within cells, reduced toxicity, and even minimal surrounding tissue to 
drugs released.16, 18-20,21  
 
They consist of a lipid bilayer built around aqueous cores lined with polar heads on the 
exteriors and non-polar tails on the inside. Liposomes are known to be multi-functional 
vehicle system with different “pockets” to efficiently store and carry various molecules to 
a biological site. Once at the site, various endogenous enzymes are helpful in the lipid 
degradation of liposomes.16  
 
Nanoparticle drug delivery facilitates ease of transport into cellular membranes and 
environments near targeted site. Unloading drugs at specific sites with reduced toxicity 
levels is important for patients with cancerous tumors for longer survival and minimal 
relapse rates.21,22 Various molecules (peptides, antibodies, carbohydrates) bound to the 
nanocarriers are also recent progressive advances for more effective therapeutic 
approaches in cancer treatments. Nanoparticle and cellular membrane interactions are 
therefore important to gain a deeper knowledge of structural and thermodynamic properties 
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at a molecular level. Cell membranes are composed of a complex phospholipid bilayer 
barrier and act as a protective layer. Bilayers in membranes are essential for 
communication to external stimuli to internal areas in the cell. Fickian diffusion occurs to 
allow small molecules but any polar or larger molecules require protein carrier mediated 
transport. Particularly, these larger molecules use a bulk transport method known an 
endocytosis to travel between membranes and cytosol components. Nanoparticles (NPs) 
also participate in endocytosis when coming to contact with cellular membranes but do not 
necessarily need receptor mediated processes. Various studies have gathered that these 
phospholipid membranes are easily flexible and deformed when NPs arrive, pushing the 
cell to “swallow” NPs into cytosol and cytoplasm areas. For the cell to engulf these NPs, 
adhesion energies in the membrane must match to the energy needed to wrap around 
circumference of nanoparticle. Specifically, cationic molecules are utilized for drug 
delivery applications for their strong adhesion and “internalization” to opposite charged 
membranes.23,24  
 
Polymer based nanoparticles (NPs) have been a rising area of focus in cancer therapy for 
various drug delivery systems. The use of polymers in the system allows for narrow size 
distribution and increased encapsulation efficiencies which are desirable features of drug 
loaded NPs. Drug loading into NPs are also an important point to consider when 
synthesizing these molecules.13, 25 Many studies have used polyethylene glycol (PEG) 
coated or loaded nanoparticles for higher stability in in-vitro and in-vivo settings as it can 
withstand circulation challenges from the reticuloendothelial system (RES).26 Also, when 
testing in cells (in vitro and in vivo), polymer nanoparticles are known to provide extra 
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protection against any enzymatic degradation naturally occurring in the body as well as 
controlled release of drugs to tumor sites.26,27,28 Many studies have shown that use of 
polymer nanoparticles for combination therapies in cancer have great cytotoxicity effects 
both in vitro and in vivo depending on the synthesis and characterization of NPs. Obtaining 
appropriate sized nanoparticles to assure efficient transport into tumor cells with minimal 






















Recent advances in nanotechnology and drug delivery systems offer areas of improvement 
and novelty in cancer therapies. Use of polymer based nanoparticles for various cancer 
treatments is helpful in protecting encapsulated drugs in the body until appropriate release 
times. We employed this foundation in our study with combination of chemotherapeutic 
drugs in Triple Negative Breast Cancer to obtain higher and effective cell death at low 
concentration treatments.  
 
FDA approved drugs that are Topoisomerase II and PARP inhibitors, mitoxantrone and 
olaparib, respectively were encapsulated in polymer-liposome complexes for synergistic 
effects on tumor cell death. The interactions between both these drugs are beneficial in 
TNBC therapies, due to the lack of receptors on TNBC tumor cells. Here, we report a novel 
aminoglycoside derived polymer liposome complex with encapsulated anticancer drugs for 
TNBC studies. To our knowledge, this is a novel approach of combination therapy 
targeting DNA damage in TNBC tumors. Our aim is to also test these novel liposomes in 
cancer cell lines while studying apoptotic pathways, various pre-clinical settings, to 









Reagents. 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC), Cholesterol,  PARP 
inhibitors (Olaparib, Veliparib), MTT reagent, dimethyl sulfoxide (DMSO) and 
Chloroform were purchased from Sigma-Aldrich St. Louis, USA. All reagents were used 
without any further purification. The anticancer drug, Mitoxantrone was purchased from 
Ontario chemicals, Canada.  
 
Preparation of liposomes. PARP inhibitors (Olaparib or Veliparib), Cholesterol, and 1,2-
Dioleoyl-sn-glycero-3-phosphocholine (DOPC) in (0.25-1):1:1 molar ratios were 
dissolved in a mixture of chloroform in a glass vial, Mitoxantrone stock solution (1 wt % 
in 1:1 chloroform:methanol) in a 0.25-0.5 molar ratio was then added to this vial containing 
mixture of compounds. The solvent was removed using a low flow of moisture free air and 
the dried lipid film was then kept under high vacuum for 8 h. 1 mL of sterile 1X PBS 
(phosophate buffered saline) (for preparing liposomes containing 1 mM DOPC, (0.25-1) 
mM PAPR inhibitors and 1 mM cholesterol) was added to the vacuum dried lipid film and 
the mixture was allowed to swell overnight to form hydrated films. The vials were placed 
in the vortex mixer for 3 minutes at room temperature to yield multilamellar vesicles 
(MLVs). MLVs were then first bath sonicated for 5–6 min and followed up with probe 
sonication for 1-2 min keeping in an ice bath using a Sonifier at 100% duty cycle at 35 W 
output power for appropriately sized small unilamellar vesicles (SUVs). Given the 
liposome synthesis described above, since mitoxantrone and PARP inhibitors are highly 
hydrophobic, they are expected to be localized within the hydrophobic lipid bilayer of 
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liposomes. The liposomes were finally centrifuged for 20 min at 13000 rpm to precipitate 
out unencapsulated mitoxantrone. The amount of mitoxantrone entrapped in liposomes 
(supernatant) was quantitated by spectrophotometric absorbance measurements at λmax of 
mitoxantrone (450 nm) by lysing the liposomal solutions with Triton X-100 (1%) and 
dissolving the lysed solutions in methanol. The concentrations (µg/mL) of the liposomally 
encapsulated mitoxantrone were then calculated from a standard calibration graph 
constructed by measuring absorbance of six different known concentrations of 
mitoxantrone of at 450 nm.  
Characterization of liposomes. Hydrodynamic sizes and zeta potential values of 
liposomes were determined using a Zetasizer Nanosystems Nano-ZS instrument (Malvern 
Instruments, Mission Viejo, CA). The sizes of empty liposomes and mitoxantrone 
encapsulated liposomes were measured using 150 µL of corresponding liposomes. Zeta 
potentials or surface charges were measured using 150 µL of liposome stocks with 850 µL 
of nanopure water. Zeta potential and size distribution measurements were carried out in 
triplicate and all the liposomal solutions were incubated at room temperature. Liposomes’ 
Size and zeta potential stability was investigated by assessing change in hydrodynamic 
diameter of liposomes with time (7, 30 and 60 days) using the Zetasizer Nanosystems 
Nano-ZS instrument. The procedure is as earlier demonstrated under this section; the 
results were showed on a table.  
Cell Culture. MDA-MB-231 (Triple negative breast cancer), PC3-PSMA (human prostate 
cancer), UM-UC3 (human bladder cancer), and MDA-MB-468 (Triple Negative Breast 
Cancer) cells were procured from the American Type Cell Culture (Manassas, VA). All 
cells were cultured in DMEM media supplemented with 10% v/v fetal bovine serum (FBS) 
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and 1% penicillin-streptomycin (10000 units/mL) solution. All cell lines were maintained 
at 37 °C under an atmosphere of air (95%) and carbon dioxide (5%) in an incubator. At 
approximately 80% confluence, cells were trypsinized with 0.25% trypsin-EDTA and 
seeded at a density of 10,000 cells/well in 96-well plates (Corning, Corning, NY, USA) for 
all cell viability experiments. 
Cell Viability studies. MDA-MB-231, PC3-PSMA, UMUC-3, and MDA-MB-468 Cells 
were plated in 96 well plates at a density of 10,000 cells/well and cells were incubated at 
37°C and 5% CO2 for approximately 24 hours prior to the treatment. Four different 
concentrations (0.625µM, 1.25µM, 2.5µM, and 5µM) were employed to the efficacy of the 
liposomes. The cell viability was determined using the MTT (3-(4,5-dimethylthiazolyl-2)- 
2,5-diphenyltetrazolium bromide) assay (described below). The empty and Mitoxantrone 
loaded liposomal treatments were carried out using concentration range of 0.625 µM-10 
µM. The experiment was carried out for 48 hours to know the effective formulation and 
dosing.  
Absorbance Spectroscopy. Following MTT Cytotoxicity assay to the samples, the 
absorbance spectra of the cells with the different treatments of liposomes were measured 
using a BioTek Synergy 2 plate reader. The measurements are taken at both 570 and 670 
nm, which gives a good indicator of the amount of light absorbed in the samples. Samples 
with less tumor cells are less of a purple color, are indicated for less viable or living tumor 
cells, which is then indicated by lower absorbance values read by the instrument. 
Absorbance values at 670 nm were subtracted from 570 nm, to give the actual values, 
which are then analyzed accordingly.  
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Western Protein Analysis. For protein expression analysis, cells were lysed in 
radioimmunoprecipitation assay (RIPA) buffer (Thermo Scientific, Waltham, MA, USA) 
at 4°C. Immunoblotting was performed for all samples with standard procedures. Protein 
assaysw were run (Thermo Scientific , PierceTM BCA Protein Assay Kit) on lysed protein 
in MDA-MB-231 cells to obtain corresponding protein amounts in a set volume. Briefly, a 
total of 135 µg of protein was resolved and run by 4%–20% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) at 200 V for 32 minutes, and then 
transferred on to wet nitrocellulose membranes and run at 20 V for 45 minutes. The transfer 
membranes were then probed with both primary (Rabbit mAb) and secondary rabbit 
antibodies. For this study, the primary antibodies used were: Capase-3 and TNF-alpha (Cell 
Signaling Technology, Danvers, MA, USA), Topoisomerase II Beta, RAD51C (Abcam, 
USA). β-actin (Sigma-Aldrich) was used as the loading control for all studies in dilutions 
of 1:250 to 1:10,000. 
 
Confocal Microscopy. MDA-MB-231 cells were seeded onto glass coverslips at 10 x104 
cells/ml in 24 well plates overnight. Twenty hours following plating, cells were treated 
with empty, single, and combination drug liposomes and kept at 37°C and 5% CO2 for 5 
hours. Following incubation, media was removed from cells and 1X PBS was washed and 
added to each well plate. Coverslips were then removed from well plates and inverted on 
to microscope glass slides containing Fluorogel (Electron Microscopy Sciences, 17985-
10). Coverslips containing cells were then sealed with top coat gel and wrapped in 
aluminum foil to avoid light interference with samples. Cells were examined under a Leica 
SP5 laser scanning fluorescence confocal microscope. 
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RESULTS & DISCUSSION 
 
Using a novel nanoparticle based drug system is influential in bringing alternative methods 
for clinical treatments for Triple Negative Breast Cancer. Synthesizing a system that can 
eventually become targeted for tumors with a lack of receptors can have significant 
implications in the oncology field. In addition, having a synergistic combination treatment 
might have the foundation for solving challenges such as the above in the field. In this 
study, we report a novel polymer based liposome that can deliver chemotherapeutic drugs 
(mitoxantrone and olaparib) targeting DNA helix strand damage. Aminoglycoside 
polymers synthesized in the lab have both hydrophilic and hydrophobic components, 
mitoxantrone and olaparib are hydrophobic drugs, along with neutral co-lipids that are non-
polar components (Figure 2.3.1).  
 
The ability to encapsulate and deliver chemotherapeutic drugs can have a significant 
impact in tumor ablation in many cancer types. Previous studies have shown that liposome 
encapsulated mitoxantrone significantly improved anti-tumor activity specifically in breast 
cancer treatments. In addition, encapsulated doxorubicin (common anthracycline 
derivative) in liposomes revealed lower cardiotoxicity in patients compared to free drug 
treatments.29,26 Other nanoparticle vehicles with mitoxantrone and olaparib (single agent) 










Figure 2.3.1. Schematic of final liposome synthesized with encapsulated drugs, co-lipids 
and novel aminoglycoside polymers for in-vitro studies. (A) General liposome visual 
schematic. Co-lipids constitute the liposome structure as depicted by the bi-layer of 
hydrophobic components. (B) chemical structures of hydrophobic and hydrophilic 


























Figure 2.3.2 Schematic of Liposome Synthesis and Cell Treatment Processes. 1mM final 
liposome solutions are formulated in 1:1 chlorofoam and methanol and then evaporated 
to create a thin-film lipid layer through a freeze drying process. Then, 1X PBS is added 
as a buffer to help swelling of drugs and lipids. Samples are placed through a sonication 















Initially, 1 wt% stocks of various components for liposome synthesis are prepared in a 1:1 
chloroform methanol solution. Preliminary experiments included various novel polymers 
weighed out and dissolved at 2.5wt% in the same above solution, to assure uniformity 
mixing. Having both non-polar and polar components in our synthesized polymer is helpful 
to maintain a balance of types of encapsulated molecules in the amphiphilic nanoparticle. 
Taking appropriate amounts of each component (including polymer) into 3mL scintillation 
vials, a vacuum source is applied for a thin film layer of chemicals by drying out solvents. 
After all amounts of solutions were added to scintillation vials, air vacuum (sufficient for 
small volumes) was used to create a thin-film layer. This establishes the first step of 
promoting the liposome structure with a lipid bi-layer.30,31 Neutral lipids typically have a 
gel-liquid crystal transition temperature at 1oC or less so a popular hydrating medium is 
usually water of 1X PBS. In this study, 1-2 mL of 1X PBS was added to scintillation vials 
(1mM liposome) for swelling of liposomes overnight. After sonication and vortex steps the 
following day, liposomes finally form the multimellar vesicular form to then be used for 
characterization and toxicity studies.16, 30 In the liposomes, the hydrophilic (aqueous) core 
contains the neomycin group which is instrumental in its affinity of binding to 
Phosphatidylinositol 4,5-bisphosphate (PIP2), an important lipid component of cell 
membranes.22,31 The anti-cancer drugs, mitoxantrone and olaparib are encapsulated in the 
hydrophobic areas of the liposome, as indicated in Figure 5. As mentioned earlier, 
liposomes are an attractive source for delivering both hydrophilic and hydrophobic 
drugs.6,32 The hypothesis was formed on the basis of liposomal delivery of combination 
drug being more effective than free drug treatments. This can be explained due to potent 
stability of nanostructures over extended periods of times, high surface charges from 
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conjugation to aminoglycoside polymers, and ability to facilitate effective drug loading. 
This should be a tactful technique to observe in comparison to free drug treatments. 
The neomycin glycerol polymer with a C18 chain (NGC18 1:2) is produced from cross-
linking of neomycin monomers to glycerol diglycidyl ethers cross linkers. Using 
aminoglycoside polymers in drug delivery is attractive for its many unique properties as 
mentioned earlier.33,37 These molecules are a major subset of antibiotics that are 
particularly helpful in minimizing multidrug resistance from various pathogens, making it 
useful in drug delivery applications. Aminoglycosides are small molecules with sugar, 
hydroxyl, and amine moieties with unique properties such as high hydrophilicity and 
versatile chemistries through slight structural modifications, making it an attractive source 
for various applications in the field. In addition, aminoglycosides have shown to  have the 
capability to bind to bacterial regions in eukaryotic RNA and DNA.24,34 Previously, 
aminoglycosides have been used as starting materials in polymers conjugated to DNA 
plasmids35, as well as novel DNA binding ligands.28  In this study, novel aminoglycoside 
derived liposomes were encapsulated with mitoxantrone and olaparib for effective drug 









Liposome Characterization Studies 
Four groups of liposomes were formulated for all studies carried out. Empty Liposomes 
(EL) contain only polymer and co-lipids cholesterol and DOPC. Single agent liposomes, 
mitoxantrone liposomes (LM) and olaparib liposomes (LO) have components of EL and 
are encapsulated with 11uL of 1 wt% stock solutions mitoxantrone or olaparib, 
respectively. Combination treatment liposomes (LMO) had both mitoxantrone and olaparib 
with co-lipids and synthesized polymers. Characterization studies further on were carried 
out on four primary groups of liposomes. Dynamic light scattering was used for size and 
zeta potential studies with diluted solutions of liposome solutions in NPW. Obtaining an 
appropriate nanometer size and positive surface charge was the aim of these studies in order 
to assure binding of amines to negative membranes in the DNA backbone. Various 
formulations were carried out in this study and results of sizes, surface charges, and 












Table 2.3.1 (A) DLS characterization studies of groups of various polymer conjugated 
mitoxantrone only liposomes. (B) DLS characterization studies of single drug and 
combination drug liposomes. Corresponding poly-disperse indexes (PDI), nanoparticle 








LPSM 1  
Neomycin 
Glycerol 
0.19 113 34 ± 3.0 
Control  0.43 257 24 ± 7.6 
LPSM 2  
Paromycin 
Glycerol 
0.16 117 33 ± 3.3 
Control 0.30 195 26 ± 6.7 
LPSM 3  
Paromycin 
Resorcinol 
0.24 198 36 ± 4.3 
Control 0.21 229 25 ± 4.8 
LPSM 4  
Aromycin 
Resorcinol 
0.19 158 37 ± 6.8 
Control 0.24 186 32 ±5.4 
LPSM 5  
Neomycin 
Glycerol 
0.17 143 32± 6.6 
Control 0.84 227 23 ± 6.5 














The mitoxantrone encapsulated liposomes revealed lower hydrodynamic diameters and 
higher zeta potential values than their respective controls (without mitoxantrone), 
indicating their implication for drug delivery applications, both in vitro and in vivo settings. 
Nanoparticles at 200 nm or less are considered effective due to longer circulation time due 
to increased stability and uptake by EPR effects in the body. Enhanced permeability and 
retention (EPR) effects describe the leaking process of nanoparticles leak into tumor tissue 
through permeable tumor vasculature and are able to stay in the area with reduced 
lymphatic drainage. Therefore, our characterization studies seemed promising for drug 
delivery applications. Higher surface charge densities are likely due to presence of amines 
from neomycin or paromycin groups on outer surface of liposomes (Table 1.3.1). There 
was not a significant difference in zeta potential of liposomes synthesized of neomycin or 
paromycin. These liposomes included only encapsulated mitoxantrone with various 
polymers. Stability of these liposomes were tested over a time of two months. Liposomes 
with encapsulated mitoxantrone are stable over long periods of time (Table 2.3.2), and 











Liposome Polymer Hydrodynamic Diameter (nm) Zeta Potential (mV) 
  1 month 2 month 1 month 2 month 
1 NGC18 1:2 132 ± 1 132 ± 2 132 ± 3 132 ± 1 
2 PGC18 1:2 127 ± 2 127 ± 2 127 ± 2 127 ± 2 
3 PRC18 1:2 138 ± 2 138 ± 2 138 ± 2 138 ± 2 
4 ARC18 1:2 158 ± 2 158 ± 2 158 ± 2 158 ± 2 
 


























































 Neomycin Glycerol 
Diglycidyl Ether  
(NGC18 1:2) 
Paromomycin Glycerol 
Diglycidyl Ether  
(NGC18 1:2) 
Average Size (nm) 91 ± 13 62 ± 14 
 
Figure 2.3.3 Transmission Electron Microscopy (TEM) Images of Liposomes. Structural 
morphologies of (A) mitoxantrone encapsulated liposomes synthesized with 
Paromomycin glycerol diglycidyl ether and (B) mitoxantrone encapsulated liposomes 
synthesized with Neomycin glycerol diglycidyl ether. Cells with respective treatments 
were visualized under transmission electron microscopy (TEM), which gives images on 
nanoparticle sized structures. (C) Average sizes of liposomes with the various polymers 

















































































R2= Resorcinol diglycidyl linker
 
 
Figure 2.3.4 Aminoglycoside Parental Polymer Synthesis. Monomers were cross-linked 
with resorcinol diglyceryl ethers and then reacted with alkyl acid chlorides (hydrophobic 
























































Figure 2.3.5 High Performance Liquid Chromatography (HPLC) Calibration Curves for 
Loading Studies. (A) Mitoxantrone Calibration Curve and (B) Olaparib Calibration 





































Calibration studies for loading of drugs into liposomes were conducted using High 
Performance Liquid Chromatography (HPLC) methods. HPLC methods were run at 
mobile phase, at 0.25 mL/min flow rate in a C18 column with a absorbance detector, 248 
nm and 625 nm, for olaparib and mitoxantrone, respectively. Concentrations of drugs were 
suspended in 80:20 acetonitrile: water and then run through HPLC to detect corresponding 
absorbances. To detect loading of mitoxantrone and olaparib, single agent and combination 
liposomes were also loaded into the HPLC and then compared against calibration curves. 
Liposomes with encapsulated drugs showed efficient drug loading of 20-23% for both 
mitoxantrone and olaparib. These reported values from our study are considered high and 
sufficient enough for treatments. The loading range is suitable for drug applications as there 




Initially, mitoxantrone only encapsulated liposomes were tested in various cancer cell lines 
to observe effect on cell death (Figure 4 – 6). Cell viability was measured using an MTT 
assay across cell lines which shows the measure of “viable” or living cells and is usually 
determined with various assays surrounding cell function, apoptosis, and cell proliferation. 
Across UMUC-3, PC3-PSMA, and MDA-MB-231 cell lines, cell death for liposomes were 
significantly lower (p < 0.001) in comparison to mitoxantrone free drug and control 
liposomes (empty) treatments. In MDA-MB-231 (TNBC cell line), mitoxantrone free drug 
treatments resulted in viabilities between 35% and 20% for 2.5 µM and 5 µM, respectively. 
At the same concentrations, 2.5 µM and 5 µM, liposomes encapsulating mitoxantrone had 
viabilities 15% and < 10%, respectively. With aminoglycoside polymers giving a higher 
surface charge density, the liposome is able to bind efficiently to hyaluronic molecules in 
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proteoglycans, an important constituent of the cell membrane. Liposomes were most likely 
transported across the cell membrane through an endocytosis process as the liposomes 
would be absorbed and form into endosomes.37 After damaging and breaking through the 
cell membrane, these positively charged liposomes (endosomes) effectively bind to 
negative DNA molecules, to release Mitoxantrone as the endosome is cleaved by various 
intracellular enzymes at the nucleus site.37,38 Even if nanoparticles are slightly bigger in 
size, drugs or any genetic material can still interact with nuclear DNA when mitosis 
occurs.38, 39 The release of mitoxantrone from liposomes at nuclear DNA site is assumed to 
be significantly higher than free drug treatments after efficient transport through the cell 
membrane, resulting in higher cell death. This assumption will later be shown through 
nanoparticle uptake studies through confocal microscopy.  
 
This reveals the efficacy of single agent liposomes across three cancer cell lines, with 
highest cancer cell death in MDA-MB-231 (Figure 4). Breast cancer cells also have a 
higher tendency to be more BRCCA-1 mutated, making them more sensitive to 
chemotherapeutic drugs.40 With this deficiency, BRCA1 genes are not properly recruited 
to DNA damage sites by the specific RAP80 mediators. MDA-MB-231 (TNBC cell line) 
had the highest. Employing these specific drug treatments in cell lines with possible 
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Figure 2.3.6 MTT Cell Viability of Mitoxantrone encapsulated liposomes in MDA-MB-
231 (TNBC) cells. Various polymers were used with the single agent liposomes to 
determine efficacy of liposome mitoxantrone in comparison to free drug and unloaded 
liposome treatments. Results were recorded 48 hours post drug treatments. Asterisks 
indicate statistical significance (n=3) between olaparib free drug and combination with 
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Figure 2.3.7 Mitoxantrone encapsulated liposomes with olaparib free drug treatments in 
MDA-MB-231 cell culture at (A) 1.25 𝝁M liposomal concentrations and (B) 2.5 𝝁M 
liposomal concentrations. Asterisks indicate statistical significance (n=3) between 






































2.5 𝝁M Mitoxantrone Liposomes with PARPi  1 uM 2 uM
****
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Cytotoxicity of Combination Treatments in MDA-MB-231, PC3-PSMA, UM-UC-3 
Cells 
Mitoxantrone encapsulated liposomes were further tested across the same cell lines in 
combination with olaparib and veliparib free drug treatments (Figure 2.3.7). Both are well 
known PARP inhibitors that are established in phase II and III in clinical trials, with minute 
differences between them. MTT cell proliferation assay was conducted to obtain cell 
viabilities across cell lines in response to mitoxantrone encapsulated liposomes with both 
PARPi free drug treatments. Significant cell death was observed in mitoxantrone liposomes 
with olaparib and veliparib free drugs in comparison to their respective controls. 
Additionally, significant cell death was seen when comparing the liposome treatments to 
both free drug controls and liposome with only olaparib or veliparib. This proves that there 
is synergistic cell death that is higher than individual agents in liposomes. Higher 
significance (**, p < 0.01) of cell death in liposomes compared to PARPi free drug controls 
was seen in PARPi concentrations at 2 µM (liposomes constant at 1.25 µM). Additionally, 
mitoxantrone encapsulated with PARPi free drug treatments (Figure 2.3.6 displayed higher 
cell death at 1.25 µM in comparison to mitoxantrone single agent liposomes (Figure 2.3.7 
). It is important to note the lower cell viabilities obtained in the MDA-MB-231 cell line 
with the lack of 3 receptors, making this combination therapy effective. Additionally, a 
majority of TNBC cells are considered to be BRCA-1 deficient or defective, making them 
more sensitive to DNA damaging agents such as the ones in our liposomal treatments. 
Using a PARP inhibitor is especially useful here as it promotes damaged DNA to enter the 
next cell phase (mitosis), ultimately leading to apoptosis.41, 27 All cell lines showed 
statistical significance, proving the efficacy of combination treatments of mitoxantrone and 
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PARPi agents in drug delivery applications. Negligible differences were noticed between 
olaparib and veliparib in performance in liposomal treatments, however, olaparib was used 
moving forward. Studies have shown that olaparib held higher binding affinities to the 
PARP complex for more effective inhibition of repair pathways, making it more prevalent 


































Table 2.3.2 DLS characterization studies of groups of single and combination treatments 
of drugs (mitoxantrone and olaparib). Values from studies were taken from n=4 





Zeta Potential (mV) 
Unloaded Liposome 174 ± 6.28 23.6 ± 3.2 
Liposome Olaparib (LO) 176 ± 3.89 23.1 ± 1.4 
Liposome Mitoxantrone 
(LM) 
184 ± 1.23 28.4 ± 2.6 
Liposome Mitoxantrone 
& Olaparib (LMO) - 
Combination 


























        
 
Figure 2.3.8 MTT Cell Viability Assay of Liposomes: Various Formulations of 
Combination Drug Liposomes in TNBC Cells. Acronyms stand as the following: OLA – 
Olaparib, MTX- Mitoxantrone, LO- Olaparib Liposomes, LM- Mitoxantrone Liposomes. 
Asterisks indicate statistical significance (n=3) between groups shown on graph 
combination versus single drug liposomal treatments (*, indicates p-values < 0.05; **, 

































                                                                                                                                                                                                                                                                                                                                                                                                          
Figure 2.3.9 MTT Cell Viability Assay of Liposomes: 1:2, 1:5, 1:10 Olaparib single 
agent, and Combination drug liposomes in MDA-MB-231(TNBC) cells. Asterisks 
indicate statistical significance (n=3) between groups shown on graph combination versus 







































MDA-MB-231 1.25 µM 2.5 µM








Figure 2.3.10 MTT Cell Viability Assay of Liposomes: Empty (unloaded), Mitoxantrone 
single agent, Olaparib single agent, and Combination drug liposomes in MDA-MB-468 
(TNBC) cells. Asterisks indicate statistical significance (n=3) between groups shown on 
graph combination versus single drug liposomal treatments (*, indicates p-values < 0.05; 



























MDA-MB-468 1 𝝻M 2.5 𝝻M
5 𝝻M 10 𝝻M**	
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Characterization Studies of Encapsulated Mitoxantrone and PARPi  
After observing synergistic effects of Mitoxantrone with free drug PARPi in various cell 
lines, the ultimate goal was to develop a liposome where both components are efficiently 
encapsulated and delivered at target tumor sites. For the following cell treatments, 
liposomes with both drugs encapsulated were synthesizes along with controls of single 
drug liposomes and empty or unloaded liposomes. Dynamic Light Scattering was again 
used to perform characterization studies of both size and zeta potential in all samples. 
Liposome sizes were in an appropriate range below 200 nm (Table 2.3.2), however they 
were bigger in diameter in comparison to Mitoxantrone (single agent) liposomes (Table 
2.3.1). This could be due to the fact that the combination liposomes are bulkier with 
additional PARPi molecules. The zeta potential or surface charge is still high and depicts 
samples as cationic liposomes for ease of delivery through cellular and nuclear membranes. 
Having highly cationic particles is beneficial in damaging cell membrane and 
mitochondrial function, allowing drugs to penetrate targeted area.29 All nanoparticles were 
in the range of 170-185 nm with surface charges in the range of 23 – 26 mV.  
Cell Treatments of Encapsulated Mitoxantrone and PARPi 
Empty (unloaded), single drug, and combination encapsulated liposomes were tested in 
MDA-MB-231 (TNBC) cells. Here, the synergistic effect of dual or combination drug 
treatments was off interest. Various molar ratios of mitoxantrone to olaparib were tested 
(1:0.25, 1:0.5, 0.25:0.25, respectively) with their respective controls of empty liposomes 
(Figure 2.3.8). Higher cell death was observed in all combination treatments with respect 
to controls, but highest cell death was in 0.25:0.25 (mitoxantrone : olaparib) liposomes. 
Equivalent molar amounts were needed in order to effectively damage DNA in tumor cells 
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and inhibit repair pathways, making this formulation an important one to move forward 
with in cell and pre-clinical settings. Encapsulating both drugs in liposomes proved to have 
synergistic and higher cell death than single drug treatments of both mitoxantrone and 
olaparib (Figure 2.3.8). A 50 to 70 % increase in cell death in dual treatments was observed 
at both 1µM and 2µM PARPi (olaparib) treatments when compared to single drug 
liposomal treatments. Liposomes were then formulated with higher ratios of PARPi in 
comparison to mitoxantrone (1:2, 1:5, 1:10; mitoxantrone : olaparib, respectively). This 
study was performed to see if there still is effective and synergistic cell death between both 
drugs in comparison to single agent treatments (Figure 2.3.9). We observed decreased cell 
death in 1:2, 1:5 mitoxantrone : olaparib in comparison to 1:10 formulated liposomes. 
Therefore, it can be assumed that because there are significantly lower amounts of 
mitoxantrone in comparison to PARPi or olaparib, a significant amount (~10 fold increase) 
is needed in order to obstruct PARP repair pathways, which create a scaffold for other 
essential repair proteins. Molar ratios of 1:2 and 1:5 are not as effective because there is 
not enough mitoxantrone (compared to olaparib) supplied for effective DNA damage, so 
an abundance of PARPi molecules are necessary to stop tumor cells from attempting repair. 
Empty, single, and combination drug liposomes were tested in an additional TNBC non-
metastatic cell line, MDA-MB-468. Cell line variations were observed with same treatment 
conditions in different cells, which are bound to exist due to origins of where cell lines are 
extracted from. However, similar trends were seen with synergistic and significant cell 
death of dual drug liposomes in comparison to unloaded and single drug treatments, 
making our combination liposome vehicles an effective drug delivery application.  
Confocal Microscopy  
 46 
Mitoxantrone containing liposomes and free drug treatments were observed under 
Confocal Microscopy to observe nanoparticle uptake versus free drug treatments (Figure 
2.3.11). These images show efficient nanoparticle uptake in both single drug and 
combination with PARPi liposomes as indicated by the red fluorescence shown into cells 
present in the sample matrix. Free drug treatments were also effective in cell uptake, with 
no significant differences between free drug and nanoparticle or liposome uptake by cells. 
However, this supports the fact that no compromise of liposome uptake by cells is made, 
as efficient transport is still maintained. Our liposomes are effective in treatment of TNBC 
cells, as seen by efficient uptake and corresponding cell death of liposomes with MTT cell 
viability assays. During MTT cytotoxicity testing (Figures 2.3.6 to Figures 2.3.9), 
liposomes were significantly effective in higher tumor cell death, which could be due to 
higher uptake of liposomal endosomes into nuclear membranes. Aminoglycoside polymers 
used in the liposomes would be instrumental here with its high binding affinity to 





     
 
Figure 2.3.11 Confocal Microscopic Images of Liposomal and Free Drug Treatments in 
MDA-MB-231 cells. MDA-MB-231 cells treated at 10µM with: mitoxantrone free drug 













Figure 2.3.12 Hypothesis of apoptotic pathway via RAD51C expressions from liposomal 































Figure 2.3.13 Densitometry measurements (n=3) of (A) RAD51C Expression in MDA-
MB-231 Cells with Single and Combination Drug Liposomes, (B) RAD51C Expression 








































Figure 2.3.14 Hypothesis of apoptotic pathway via Top-II β expressions from liposomal 












Figure 2.3.15 Densitometry measurements (n = 3) of (A) Topoisomerase II β Expression 
in MDA-MB231 (TNBC cells) in Single and Double Agent Liposomes, (B) 
Topoisomerase II β Expression Images of Liposomes and respective β actin controls. 









































Figure 2.3.16 Hypothesis of apoptotic pathway via Caspase-3 expressions from 





















Figure 2.3.17 Densitometry measurements (n=3) of (A) Caspase-3 Expression in MDA-
MB231 (TNBC cells) in Single and Double Agent Liposomes, (B) Capase-3 Expression 
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Apoptosis Protein Analysis 
Protein Analysis (Western Blots) were conducted (n=3) to understand the pathways that 
liposomes were involved in leading cancer cells to programmed cell death or apoptosis. 
RAD51C, a significant protein in PARP related activity was one of the few biomarkers 
evaluated in our studies. RAD51C is a participant in the family of RAD51 protein genes 
that helps maintain genomic stability in cells through double strand break (DSB) repairs 
and participates in many subsets of the family. Cells that lack any sets of the RAD51 
paralogue are more sensitive to chemotherapeutic agents, radiation, and other factors.42,43,44 
Studies have shown that RAD51C is highly response to DSBs with increasing foci in 
response to DNA damage over various time periods. Additionally, studies have been 
conducted revealing that RAD51C is instrumental in delaying progress of defective cells 
(post DNA damage) through cell cycle (G2-M phases).45,44,46 With its many roles in the 
DNA damage repair process from control homologous recombination activation to 
filament assembly in RAD51 paralogues, RAD51C was of interest for its expression in 
response to PARP inhibitor treatments. A particular study also investigated the effects of 
PARP inhibitors on RAD51C deficient cells. Olaparib induced apoptosis pathways was 
seen in cells without RAD51C proteins.44,46,47 Therefore, for our study, we hypothesized 
that with olaparib treatments, RAD51C proteins would be suppressed, leading to higher 
cell death via activated apoptotic pathways (Figure 2.3.12). As Olaparib is PARP inhibitor 
and prevents DNA damage repair pathways to activate, RAD51C and its paralogues should 
be restrained and not able to recruit subsequent proteins. This down regulation of RAD51C 
should then force the tumor cells to proceed further in the cell cycle and lead to apoptosis. 
The expected down regulation of RAD51C expression can be observed in response to 
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olaparib liposomal treatments that aid in inhibiting repair pathways recruited by RAD51 
protein paralogues (Figure 2.3.13). Figure 2.3.13 (B) shows all concentrations tested for 
each sample corresponding with Figure 2.3.13 (A).  It can be concluded that with increased 
PARP inhibitor sensitivity in the cells, the cell DNA repair protein, RAD51C is stopped 
from arriving at site to perform its functions. Also, RAD51C is an instrumental part in the 
17q23 chromosomal region, a popular spot for estrogen genes, which is commonly linked 
to breast cancer tumors.47, 48,49 TNBC tumors therefore will be associated with RAD51C 
deficiency due to the lack of all receptors (HER, progesterone, estrogen). Seeing the results 
from our study confirmed that with the use of PARP inhibitors such as Olaparib, RAD51C 
is less expressed and is not able to recruit its consequent proteins such as CHK2 to pause 
cells in the M phase of cell mitosis.44,47  
 
Topoisomerase II- β was another biomarker studied to understand the mechanism of 
apoptosis in cells treated with the combination of our liposomes. Topoisomerase II is an 
essential enzyme instrumental for maintain topological features of DNA during cell 
replication and other processes to properly maintain function. The apoptosis pathway is 
known to be as follows: Mitoxantrone binds to Topoisomerase II, cleavages the enzyme, 
which leads to NF-kappa B activation to result in apoptosis.50, 51  The covalent bond to 
Topoisomerase II aids in prevention of DNA strands to come together for any attempted 
replication stages.52, In the Topoisomerase II complex, there are two subunits: Top II- α 
and Top II- β, which have individual functions in helping with cell regulation and 
replication processes in DNA. Both sub units are similar in catalytic activity, however Top 
II- β is more commonly studied as it is the dominant subunit of the two. Studies have 
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showed that Top II- β levels are altered with various factors in correlation to DNA 
damage.50,52  With decreased activity of Top II- β, DNA damage possibly became 
permanent, leading the cell to irregular function, and ultimately led to apoptosis. With our 
liposome treatments in cells, the idea was to induce permanent cell DNA damage in tumor 
cells. Cells were treated with both single and double agent liposomes (combination of 
mitoxantrone and olaparib) to evaluate protein expressions of Top II- β, which then in turn 
cannot recruit other proteins for regulating cellular replication and transcription in tumor 
cells. Figure 2.3.15 displays densitometry measurements of this protein with its 
corresponding images. Single agents of both drugs displayed less expression with DNA 
damage induced by mitoxantrone, a Topoisomerase II inhibitor. Combination treatments 
show a higher magnitude of down expression of Top II- β, making apoptosis pathways 
more effective. In the combination treatments, mitoxantrone inhibits Topoisomerase II 
activity as it forms a complex between DNA molecules and the enzyme, inhibiting any 
interaction between the two. Olaparib then de-activates its repair family pathways, which 
prohibits the cell from attempt of any repair on DNA damage. The combination treatments 
suppress Top II- β activity even further, to explain the mechanism behind tumor cell 
apoptosis in MDA-MB-231 (TNBC) cells (Figure 2.3.15). Suppressing this activity 
possibly led to decreased and inhibition of replication and therefore transcription processes 
in cells, which deems the cell “dead” due to irregular function in DNA due to disrupted 
ATP levels.  
 
Caspase-3 was the final protein evaluated in our studies. Caspase-3 is a part of the caspase 
family that is responsible for various signaling functions in eukaryotic cells. They function 
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by cleaving essential proteins or enzymes needed for regular functioning, causing cells to 
die through apoptosis. This is a sound strategy in treatment of cancer cells as targeting the 
caspase family is one of the most important molecule leading to apoptosis. DNA damage 
in cells cause many proteins and chemical releases in cells, which in turn act as “death 
stimulators” and initiate caspase-8, caspase-9, and caspase-3 downstream. With our 
liposomes, the hypothesis was that inducing permanent DNA damage in conjunction with 
inhibition of repair pathways would cause up regulation of caspase-3 and other up-stream 
caspase molecules to lead cells to apoptosis (Figure 2.3.16). After DNA damage, death 
initiator molecules could activate the mitochondrial apoptotic channel (MAC), leading to 
release of cytochrome C, which is the main chemical to activate factors that allow caspase 
to activate its otherwise latent apoptotic characteristics.53, 541 The cascade of this pathway 
was interesting for our study, and was observed in the conducted experiments. When 
treated with olaparib and mitoxantrone single drug liposomes, caspase-3 expression was 
up-regulated. Mitoxantrone only liposomes, however, had higher expression levels, 
possibly due to ability to cause more forceful DNA double strand breaks. Combination 
liposomes, also had an over expression of caspase-3 levels, leading us to believe that 
cytochrome C release and other upstream apoptotic factors were activated, which are 
instrumental in programmed cell death. The interactions between all three biomarkers 
studied are interesting, as they are connected via induced DNA damage to tumor cells, as 








To our knowledge, this is the first combination treatment involving DNA damage and 
repair pathway mechanisms for Triple Negative Breast Cancer with a novel drug carrier 
system. Nanoparticles (liposomes) that were synthesized with aminoglycoside polymers 
showed promising size (120-180 nm) and stability data by maintaining their size, charge, 
and structure up to 3 months. Confocal studies also revealed the significant amount and 
fast uptake of nanoparticles into cells when treated with combination liposomes over free 
drugs. In addition to breast cancer studies, the combination treatment liposomes also 
showed significant cell death (85-90%) in low concentrations (2.5µM and higher) in other 
cell lines such as bladder (UM-UC3) and prostate (PC3-PSMA) which suggests strong 
implications of this therapeutic strategy in many types of cancer. The two-fold strategy of 
damaging and inhibiting DNA damage and repair, respectively, is an attractive strategy in 
cancer therapy to facilitate minimal cancer relapse. Combination chemotherapeutic 
therapies holds significant impact and high promise in the oncology field, for both pre-









Future work for these breast cancer studies include the following: 
• Ongoing western analysis studies to understand additional activated apoptotic 
pathways 
• Ongoing confocal microscopy studies to evaluate efficiency of nanoparticle uptake 
in comparison to free drug treatments 
• Cell cycle studies as a supplemental study to western biomarker studies using flow 
cytometry methods 
o Provides amount of cell populations in various cell cycle phases 
• Liposomes given via intravenous intra-tumor injections to TNBC tumors in 
mammary fat models of mice experiments  
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